Cargando…

Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study

Although the use of venous thromboembolism (VTE) chemoprophylaxis has markedly reduced VTE rates after hip fracture surgery, few studies have directly compared the efficacy of different anticoagulant agents in this setting. The purpose of this study was to compare outcomes of Lovenox, Eliquis, or Co...

Descripción completa

Detalles Bibliográficos
Autores principales: Joo, Peter Y., Modrak, Maxwell, Park, Nancy, Brand, Jordan, Rubin, Lee E., Grauer, Jonathan N., Bernstein, Jenna A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746777/
https://www.ncbi.nlm.nih.gov/pubmed/36732301
http://dx.doi.org/10.5435/JAAOSGlobal-D-22-00228
_version_ 1784849440132038656
author Joo, Peter Y.
Modrak, Maxwell
Park, Nancy
Brand, Jordan
Rubin, Lee E.
Grauer, Jonathan N.
Bernstein, Jenna A.
author_facet Joo, Peter Y.
Modrak, Maxwell
Park, Nancy
Brand, Jordan
Rubin, Lee E.
Grauer, Jonathan N.
Bernstein, Jenna A.
author_sort Joo, Peter Y.
collection PubMed
description Although the use of venous thromboembolism (VTE) chemoprophylaxis has markedly reduced VTE rates after hip fracture surgery, few studies have directly compared the efficacy of different anticoagulant agents in this setting. The purpose of this study was to compare outcomes of Lovenox, Eliquis, or Coumadin as VTE prophylaxis after hip fracture surgery. METHODS: The PearlDiver MHip national database was queried for patients older than 60 years undergoing first-time hip fracture surgery with no concurrent pelvic or distal femoral fractures. Prescriptions for Lovenox, Eliquis, or Coumadin were identified. Univariate and multivariate analyses of patient characteristics, 90-day incidences of VTE, adverse events, and readmissions were compared. Odds ratios (ORs) were calculated, and significance was set at P < 0.01 based on Bonferroni adjustment. RESULTS: A total of 11,384 patients were identified, with the Lovenox used for 6835 patients (60.0%), Eliquis for 1092 patients (9.6%), and Coumadin for 3457 patients (30.4%). The prevalence of 90-day VTE in the Lovenox, Eliquis, and Coumadin groups was 3.1%, 3.8%, and 5.0%, respectively (P < 0.001). Multivariate analyses adjusting for demographic and comorbidity profiles were conducted with Lovenox as the referent. Those on Eliquis had significantly lower transfusions (OR 0.52, P = 0.005), but similar rates of other outcomes including VTE (P > 0.01). Conversely, patients on Coumadin had significantly greater odds of any adverse event (OR 1.18, P < 0.001) and VTE (OR 1.58, P < 0.001). DISCUSSION: In evaluating Lovenox, Eliquis, and Coumadin as VTE chemoprophylactic agents after hip fracture surgery in anticoagulant-naïve patients, Lovenox and Eliquis had similar 90-day VTE, whereas patients on Coumadin had greater odds of 90-day VTE. Interestingly, patients on Eliquis had nearly two-fold lower odds of transfusions compared with patients on Lovenox. Although consensus on the optimal VTE prophylactic agent after hip fracture surgery does not exist, Eliquis and Lovenox may be comparable options and seem to be more effective than Coumadin.
format Online
Article
Text
id pubmed-9746777
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-97467772022-12-16 Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study Joo, Peter Y. Modrak, Maxwell Park, Nancy Brand, Jordan Rubin, Lee E. Grauer, Jonathan N. Bernstein, Jenna A. J Am Acad Orthop Surg Glob Res Rev Research Article Although the use of venous thromboembolism (VTE) chemoprophylaxis has markedly reduced VTE rates after hip fracture surgery, few studies have directly compared the efficacy of different anticoagulant agents in this setting. The purpose of this study was to compare outcomes of Lovenox, Eliquis, or Coumadin as VTE prophylaxis after hip fracture surgery. METHODS: The PearlDiver MHip national database was queried for patients older than 60 years undergoing first-time hip fracture surgery with no concurrent pelvic or distal femoral fractures. Prescriptions for Lovenox, Eliquis, or Coumadin were identified. Univariate and multivariate analyses of patient characteristics, 90-day incidences of VTE, adverse events, and readmissions were compared. Odds ratios (ORs) were calculated, and significance was set at P < 0.01 based on Bonferroni adjustment. RESULTS: A total of 11,384 patients were identified, with the Lovenox used for 6835 patients (60.0%), Eliquis for 1092 patients (9.6%), and Coumadin for 3457 patients (30.4%). The prevalence of 90-day VTE in the Lovenox, Eliquis, and Coumadin groups was 3.1%, 3.8%, and 5.0%, respectively (P < 0.001). Multivariate analyses adjusting for demographic and comorbidity profiles were conducted with Lovenox as the referent. Those on Eliquis had significantly lower transfusions (OR 0.52, P = 0.005), but similar rates of other outcomes including VTE (P > 0.01). Conversely, patients on Coumadin had significantly greater odds of any adverse event (OR 1.18, P < 0.001) and VTE (OR 1.58, P < 0.001). DISCUSSION: In evaluating Lovenox, Eliquis, and Coumadin as VTE chemoprophylactic agents after hip fracture surgery in anticoagulant-naïve patients, Lovenox and Eliquis had similar 90-day VTE, whereas patients on Coumadin had greater odds of 90-day VTE. Interestingly, patients on Eliquis had nearly two-fold lower odds of transfusions compared with patients on Lovenox. Although consensus on the optimal VTE prophylactic agent after hip fracture surgery does not exist, Eliquis and Lovenox may be comparable options and seem to be more effective than Coumadin. Wolters Kluwer 2022-12-08 /pmc/articles/PMC9746777/ /pubmed/36732301 http://dx.doi.org/10.5435/JAAOSGlobal-D-22-00228 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Orthopaedic Surgeons. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Joo, Peter Y.
Modrak, Maxwell
Park, Nancy
Brand, Jordan
Rubin, Lee E.
Grauer, Jonathan N.
Bernstein, Jenna A.
Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study
title Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study
title_full Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study
title_fullStr Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study
title_full_unstemmed Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study
title_short Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study
title_sort comparing venous thromboembolism prophylactic agents after hip fracture surgery: a national database study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746777/
https://www.ncbi.nlm.nih.gov/pubmed/36732301
http://dx.doi.org/10.5435/JAAOSGlobal-D-22-00228
work_keys_str_mv AT joopetery comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy
AT modrakmaxwell comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy
AT parknancy comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy
AT brandjordan comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy
AT rubinleee comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy
AT grauerjonathann comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy
AT bernsteinjennaa comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy